+15%

est. 2Y upside i

HealthcareSeries A

Rank

#1722

Sector

Biotechnology

Est. Liquidity

~6Y

Data Quality

Data: Low

Rubedo Life Sciences offers high-risk, high-reward equity for a job candidate.

Last updated: July 3, 2026

Bull (15%)+180%

Positive Phase 1b/2a data attracts big pharma acquisition at 3x entry valuation ($600M). Series B accelerates pipeline; exit within 3 years.

Base (40%)+55%

Series B at a modest step-up ($250-300M) funds Phase 2 trials. Valuation grows 1.5-2x over 2 years, but no liquidity event by 2028.

Bear (45%)-100%

Clinical setback or failed financing; preference stack of $70M wipes out common equity. Exit below liquidation preference, common worth zero.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Funding Intensity

400%

Total funding of $70M creates a 35% preference overhang on an assumed $200M entry valuation; common stock is deeply subordinate.

Dilution Risk

high

Series B is actively being raised; expect 20-30% dilution for new investors in the next 12 months.

Secondary Liquidity

none

No secondary market exists for this private biotech; liquidity only via IPO or acquisition.

Questions to Ask at the Interview

Strategic questions based on Rubedolife's data — designed to show you've done your homework.

  • 1

    “How would you assess the fair value of a pre-revenue biotech like Rubedo for equity compensation?”

  • 2

    “What key milestones would you track to gauge value creation over the next 2 years?”

  • 3

    “How do you weigh the risk of dilution from the upcoming Series B against potential upside?”

Community

Valuation Sentiment

Our model estimates +15% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.